Tag Archive for: odronextamab

Regeneron’s blood cancer therapy faces setback as FDA raises trial concerns

Regeneron Pharmaceuticals said the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma, raising concerns over the progress of ongoing confirmatory trials.

Read more
/by

FDA action alert: Orchard, ITF, Merck and more

The FDA’s busy March continues with six target action dates remaining on the calendar. Over the next two weeks, the regulator will decide on investigational therapies for Duchenne muscular dystrophy, chronic kidney disease anemia, a rare metabolic disorder and more.

Read more
/by